epigenomics
Sitemap Search Contact FAQs



>> Continue Deutsche Version

The information contained in this website does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the U.S. have not been established. For further important disclaimers please read here.

PRESEPT Study
Progress Update:

Date: 05.01.2010
Clinical Sites Participating: 32
Subjects enrolled: 7914
Cancers identified: 53
Cancers confirmed: 51

Enrollment goal achieved. 


Latest news:

Epigenomics AG Reports Conclusions from PRESEPT Study Audit

Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG Releases Preliminary PRESEPT Study Data

Latest update:
08-02-2010